Related Experiment Video
Updated: Aug 2, 2025
10:00
Targeting Biofilm Associated Staphylococcus aureus Using Resazurin Based Drug-susceptibility Assay
Published on: May 5, 2016
13.3K
Targeting multidrug resistant Staphylococcus aureus with cationic chlorpromazine-peptide conjugates
Apurva Panjla1, Grace Kaul2,3, Abdul Akhir4
1Department of Chemistry, Indian Institute of Technology Kanpur, Kanpur, 208016, UP, India.
Chemistry, an Asian Journal
|April 18, 2023
Summary
Novel cationic chlorpromazine peptide conjugates show potent antibacterial activity against multidrug-resistant Staphylococcus aureus. These compounds target a key bacterial enzyme, offering a promising new strategy against severe staphylococcal infections.
Area of Science:
- Medicinal Chemistry
- Microbiology
- Drug Discovery
Background:
- Antimicrobial resistance poses a significant global health threat, driving the need for new antimicrobial agents.
- Existing treatments are becoming less effective against multidrug-resistant (MDR) bacteria.
Purpose of the Study:
- To develop novel antimicrobial scaffolds targeting MDR bacteria.
- To investigate the potential of cationic chlorpromazine peptide conjugates as new antibacterial agents.
Main Methods:
- Synthesis and evaluation of cationic chlorpromazine peptide conjugates.
- Assessment of antibacterial activity against clinical MDR Staphylococcus aureus isolates.
- In silico molecular docking and molecular dynamics simulations to determine the target interaction.
Main Results:
- The compound CPWL demonstrated potent antibacterial activity against MDR S. aureus without exhibiting cytotoxicity.
- Molecular docking revealed high affinity of CPWL for S. aureus enoyl reductase (saFabI).
- Molecular dynamics simulations corroborated the inhibitory action of CPWL against saFabI.
Conclusions:
- Cationic chlorpromazine peptide conjugates represent a promising scaffold for developing new antimicrobials.
- CPWL is a potential inhibitor of saFabI, offering a novel therapeutic strategy for staphylococcal infections.
